| Chronic Kidney Diseases

Furoscix vs Nutropin AQ

Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.
Deep comparison between: Furoscix vs Nutropin Aq Nuspin 10 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsNutropin Aq Nuspin 10 has a higher rate of injection site reactions vs Furoscix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nutropin Aq Nuspin 10 but not Furoscix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Furoscix
Nutropin Aq Nuspin 10
At A Glance
SC injection
Loop diuretic
SC injection
Daily
Recombinant human growth hormone
Indications
  • Edema
  • Chronic heart failure
  • Chronic Kidney Diseases
  • Nephrotic Syndrome
  • Somatotropin deficiency
  • Turner Syndrome
  • Chronic Kidney Diseases
Dosing
Edema, Chronic heart failure, Chronic Kidney Diseases, Nephrotic Syndrome 30 mg subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total 80 mg) via On-body Infusor applied to the abdomen; not for chronic use, replace with oral diuretics as soon as practical.
Somatotropin deficiency (pediatric) Up to 0.3 mg/kg/week divided into daily SC injections; pubertal patients may use up to 0.7 mg/kg/week divided daily.
Somatotropin deficiency (adult) Weight-based: starting dose up to 0.006 mg/kg/day SC, max 0.025 mg/kg/day (age <=35 years) or 0.0125 mg/kg/day (age >35 years); or non-weight-based: starting dose approximately 0.2 mg/day SC with gradual titration every 1-2 months.
Chronic Kidney Diseases Up to 0.35 mg/kg/week divided into daily SC injections; therapy may continue until renal transplantation.
Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses 3 to 7 times per week by SC injection.
Contraindications
  • Anuria
  • History of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
  • Prader-Willi syndrome in children with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
  • Active malignancy
  • Known hypersensitivity to somatropin or any excipient
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Closed epiphysis (for growth promotion in pediatric patients)
Adverse Reactions
Serious fluid, electrolyte, and metabolic abnormalities, ototoxicity, anaphylactic or anaphylactoid reactions, aplastic anemia, toxic epidermal necrolysis, Stevens-Johnson syndrome, interstitial nephritis, necrotizing angiitis
Other reported pancreatitis, jaundice, nausea, vomiting, tinnitus, hearing loss, vertigo, dizziness, headache, thrombocytopenia, agranulocytosis, leukopenia, rash, erythema multiforme, orthostatic hypotension, injection site erythema and pain, muscle spasm, restlessness
Most common Edema or peripheral edema (adults with GHD), arthralgias (adults with GHD), otitis media and ear disorders (Turner syndrome), injection site discomfort (pediatric GHD)
Serious Intracranial hypertension, glucose intolerance, slipped capital femoral epiphysis, scoliosis progression, leukemia, pancreatitis, severe hypersensitivity reactions, hypothyroidism, hypoadrenalism, lipoatrophy
Postmarketing Anaphylaxis, angioedema, leukemia, gynecomastia (children), pancreatitis, slipped capital femoral epiphysis, osteonecrosis
Pharmacology
Furosemide is a loop diuretic that primarily inhibits sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle, producing high-degree diuresis independent of carbonic anhydrase inhibition or aldosterone.
Somatropin is a recombinant human growth hormone that binds to dimeric GH receptors on target cell membranes, triggering intracellular signal transduction; pharmacodynamic effects include skeletal growth and protein synthesis mediated via IGF-1, as well as direct effects such as lipolysis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Furoscix
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
View full coverage details ›
Nutropin Aq Nuspin 10
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
View full coverage details ›
UnitedHealthcare
Furoscix
  • Covered on 4 commercial plans
  • PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
View full coverage details ›
Nutropin Aq Nuspin 10
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Furoscix
  • Covered on 0 commercial plans
  • PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
View full coverage details ›
Nutropin Aq Nuspin 10
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Furoscix.
No savings programs available for Nutropin Aq Nuspin 10.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
FuroscixView full Furoscix profile
Nutropin Aq Nuspin 10View full Nutropin Aq Nuspin 10 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.